Stryker Corporation (NYSE:SYK) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.
Several other equities analysts have also commented on the company. Deutsche Bank AG reiterated a “buy” rating and issued a $148.00 target price (up from $135.00) on shares of Stryker Corporation in a research note on Saturday, April 29th. Zacks Investment Research upgraded Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price for the company in a research note on Monday, July 17th. Stifel Nicolaus upped their target price on Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Cowen and Company reiterated a “buy” rating and issued a $160.00 target price (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $155.00 target price (down from $158.00) on shares of Stryker Corporation in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Stryker Corporation presently has an average rating of “Hold” and a consensus price target of $144.97.
Stryker Corporation (NYSE:SYK) traded up 0.80% on Friday, reaching $139.88. 1,397,244 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $144.80 and a 200-day moving average price of $137.03. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84. The stock has a market capitalization of $52.32 billion, a price-to-earnings ratio of 31.22 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. During the same period in the previous year, the firm posted $1.39 earnings per share. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, analysts predict that Stryker Corporation will post $6.50 earnings per share for the current year.
In other news, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Floyd sold 7,381 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $144.70, for a total value of $1,068,030.70. The disclosure for this sale can be found here. Insiders sold 32,810 shares of company stock valued at $4,754,958 in the last ninety days. Company insiders own 7.40% of the company’s stock.
Large investors have recently modified their holdings of the company. Profund Advisors LLC increased its stake in shares of Stryker Corporation by 14.3% in the first quarter. Profund Advisors LLC now owns 12,666 shares of the medical technology company’s stock valued at $1,667,000 after buying an additional 1,582 shares during the last quarter. Korea Investment CORP increased its stake in shares of Stryker Corporation by 6.1% in the first quarter. Korea Investment CORP now owns 122,993 shares of the medical technology company’s stock valued at $16,192,000 after buying an additional 7,095 shares during the last quarter. Personal Capital Advisors Corp bought a new stake in shares of Stryker Corporation during the first quarter valued at $267,000. Mn Services Vermogensbeheer B.V. increased its stake in shares of Stryker Corporation by 3.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 8,988 shares of the medical technology company’s stock valued at $1,106,000 after buying an additional 268 shares during the last quarter. Finally, Van Cleef Asset Management Inc increased its stake in shares of Stryker Corporation by 1.6% in the first quarter. Van Cleef Asset Management Inc now owns 40,820 shares of the medical technology company’s stock valued at $5,374,000 after buying an additional 655 shares during the last quarter. 73.79% of the stock is owned by institutional investors.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
